Treatment Patterns in Patients With EGFR-Positive Lung Cancer: A Real-World Patient Report

EGFR Resisters co-founder Ivy Elkins presented a mini-oral at WCLC 2021 about the real-world treatment trajectories of patients living with EGFR positive lung cancer. In this abstract, she states that although osimertinib is currently considered the standard of care for first-line treatment of patients with EGFR positive lung cancer and second-line treatment for those treated with other EGFR TKIs, osimertinib is not always prescribed this way in the real world. View the presentation here.